Business Context and Reporting Period
Company: BiomX Inc. (PHGE)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: BiomX is a clinical-stage biopharmaceutical company developing phage-based therapies to target harmful bacteria associated with chronic diseases, primarily Cystic Fibrosis (CF) and Diabetic Foot Osteomyelitis (DFO). The company operates as a single segment.
Key Corporate Events:
- Acquisition: On March 15, 2024, BiomX acquired Adaptive Phage Therapeutics, Inc. (APT), expanding its pipeline with two Phase 2 assets.
- Reverse Stock Split: A 1-for-10 reverse stock split became effective on August 26, 2024. All share data in this summary is adjusted to reflect this split.
- Geopolitical Context: Operations are headquartered in Israel. The filing notes ongoing military conflict (war with Hamas and Hezbollah) but states operations have not been materially impacted to date.
Key Financial Metrics
| Metric (USD in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(17,727) | $(26,169) |
| Operating Loss | $(44,523) | $(25,348) |
| Cash and Cash Equivalents (Dec 31, 2024) | $16,856 | $14,907 |
| Total Cash, Cash Equivalents, and Restricted Cash | $17,975 | $15,864 |
| Accumulated Deficit | $(180,697) | $(162,970) |
| Long-Term Debt | $0 | $5,402 |
Note: The company prepaid its entire $10.4 million Hercules Capital term loan in March 2024.
Material Changes vs. Prior Period
- Operating Expenses: Operating loss increased by $19.2 million (76%) to $44.5 million. This was driven by:
- R&D Expenses: Increased to $24.7 million (from $16.7 million) due to Phase 2b preparations for BX004 (CF) and clinical trial costs for BX211 (DFO), plus increased workforce and rent following the APT acquisition.
- Impairment Charges: The company recognized $8.0 million in total impairments in 2024 (none in 2023):
- Goodwill impairment: $0.8 million.
- In-Process R&D (IPR&D) impairment: $3.2 million.
- Long-lived assets impairment: $4.0 million (related to the decision to cease use of the Gaithersburg, MD facility).
- General & Administrative (G&A): Increased to $11.8 million (from $8.7 million) due to acquisition-related costs and higher compensation expenses.
- Non-Cash Income: Net loss was significantly reduced by a $26.5 million non-cash gain from the change in fair value of Private Placement Warrants issued in the March 2024 PIPE. Without this, the net loss would have been substantially higher.
- Other Income: Increased to $2.1 million (from $0.4 million) primarily due to the reversal of a contract liability associated with the discontinued Atopic Dermatitis (BX005) program.
Guidance, Outlook, and Risks
Going Concern: The financial statements contain an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management believes current cash resources (including $12 million raised in February 2025) will only be sufficient to meet requirements into the first quarter of 2026. Additional capital raises are required to sustain operations.
Clinical Pipeline Outlook:
- BX004 (Cystic Fibrosis): Phase 2b study initiation expected in Q2 2025; topline results anticipated in Q1 2026.
- BX211 (Diabetic Foot Osteomyelitis): Phase 2 study topline results expected in Q1 2025.
- Discontinued/Paused: BX005 (Atopic Dermatitis) discontinued in 2024; Prosthetic Joint Infections program paused.
Key Risks:
- Liquidity: Dependence on future equity or debt financing, which may be dilutive or unavailable on favorable terms.
- Regulatory: No bacteriophage has been approved as a drug in the U.S. or EU; regulatory pathways are uncertain.
- Geopolitical: Ongoing conflict in Israel poses risks to operations, supply chain, and employee availability (reserve duty).
- Manufacturing: Reliance on third-party manufacturers; internal GMP facility in Israel is currently on hold.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $12 million raised in February 2025 to bridge the gap to Q1 2026 and the terms of any subsequent financing.
- Impairment Drivers: Review the specific assumptions used in the $8.0 million impairment charges (Goodwill, IPR&D, and Long-lived assets) to understand the impact of the stock price decline on asset valuation.
- Private Placement Warrants: Confirm the accounting treatment of the $26.5 million non-cash gain from warrant revaluation and its impact on the reported net loss.
- Israeli Operations: Assess the current status of the Ness Ziona facility and the impact of the war on clinical trial enrollment and manufacturing logistics.
- Debt Status: Confirm the full repayment of the Hercules Capital loan and the absence of other significant debt obligations.